Medivation Given Outperform Rating at Keefe, Bruyette & Woods (MDVN)
Medivation (NASDAQ:MDVN)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Keefe, Bruyette & Woods in a research note issued to investors on Friday. They currently have a $107.00 price target on the stock, up from their previous price target of $104.00. Keefe, Bruyette & Woods’ price target would indicate a potential upside of 32.21% from the company’s current price.
Shares of Medivation (NASDAQ:MDVN) opened at 80.93 on Friday. Medivation has a 52-week low of $48.15 and a 52-week high of $88.20. The stock has a 50-day moving average of $75.89 and a 200-day moving average of $71.59. The company’s market cap is $6.193 billion. Medivation also was the target of unusually large options trading on Friday. Stock investors bought 861 call options on the company. This represents an increase of approximately 295% compared to the typical volume of 218 call options.
Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, August 7th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter last year, the company posted ($0.07) earnings per share. Medivation’s revenue was up 111.1% compared to the same quarter last year. On average, analysts predict that Medivation will post $1.50 earnings per share for the current fiscal year.
A number of other firms have also recently commented on MDVN. Analysts at Stifel Nicolaus raised their price target on shares of Medivation from $83.00 to $89.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of Medivation from $100.00 to $105.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Medivation from $95.00 to $98.00 in a research note on Monday, August 4th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. Medivation currently has a consensus rating of “Buy” and a consensus price target of $96.47.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.